FREE Subscription: Join Our YouTube Channel Today
Here is the latest financial fact sheet of . For more details, see the quarterly results and share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 3.6 |
No. of shares | m | 119.57 |
% ch week | % | -2.0 |
% ch 1-mth | % | -7.9 |
% ch 12-mth | % | 7.0 |
52 week H/L | Rs | 3,150.0/1,950.0 |
No. of Mths Year Ending |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
5-Yr Chart Click to enlarge
|
---|
ALKEM LABORATORIES EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 1,589 | 2,229 | 2,468 | 2,265 | 2,720 | |
Low | Rs | 1,232 | 1,175 | 1,578 | 1,693 | 1,660 | |
Sales per share (Unadj.) | Rs | 417.5 | 489.5 | 537.9 | 615.3 | 697.9 | |
Earnings per share (Unadj.) | Rs | 56.3 | 75.7 | 53.4 | 64.7 | 96.1 | |
Diluted earnings per share | Rs | 56.3 | 75.7 | 53.4 | 64.7 | 96.1 | |
Cash flow per share (Unadj.) | Rs | 64.7 | 84.1 | 65.4 | 80.9 | 117.3 | |
Dividends per share (Unadj.) | Rs | 12.70 | 15.00 | 13.00 | 16.00 | 25.00 | |
Adj. dividends per share | Rs | 12.70 | 15.00 | 13.00 | 16.00 | 25.00 | |
Dividend yield (eoy) | % | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 | |
Book value per share (Unadj.) | Rs | 292.9 | 373.6 | 406.8 | 454.9 | 515.2 | |
Adj. book value per share | Rs | 292.9 | 373.7 | 406.8 | 454.9 | 515.3 | |
Shares outstanding (eoy) | m | 119.57 | 119.57 | 119.57 | 119.57 | 119.57 | |
Bonus/Rights/Conversions | - | - | - | - | - | ||
Price / Sales ratio | x | 3.4 | 3.5 | 3.8 | 3.2 | 3.1 | |
Avg P/E ratio | x | 25.1 | 22.5 | 37.9 | 30.6 | 22.8 | |
P/CF ratio (eoy) | x | 21.8 | 20.2 | 31.0 | 24.5 | 18.7 | |
Price / Book Value ratio | x | 4.8 | 4.6 | 5.0 | 4.4 | 4.3 | |
Dividend payout | % | 22.6 | 19.8 | 24.3 | 24.7 | 26.0 | |
Avg Mkt Cap | Rs m | 168,653 | 203,481 | 241,890 | 236,629 | 261,879 | |
No. of employees | `000 | NA | 12.0 | 13.3 | 14.1 | 14.3 | |
Total wages/salary | Rs m | 9,171 | 10,039 | 11,916 | 13,625 | 15,055 | |
Avg. sales/employee | Rs Th | NM | 4,894.2 | 4,846.4 | 5,212.3 | 5,822.6 | |
Avg. wages/employee | Rs Th | NM | 839.5 | 898.0 | 965.3 | 1,050.5 | |
Avg. net profit/employee | Rs Th | NM | 756.5 | 481.1 | 548.1 | 802.0 |
ALKEM LABORATORIES INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 49,915 | 58,525 | 64,312 | 73,572 | 83,444 | |
Other income | Rs m | 1,645 | 1,120 | 960 | 877 | 1,042 | |
Total revenues | Rs m | 51,561 | 59,645 | 65,271 | 74,449 | 84,486 | |
Gross profit | Rs m | 8,482 | 9,990 | 10,284 | 11,148 | 14,734 | |
Depreciation | Rs m | 1,006 | 1,012 | 1,430 | 1,932 | 2,528 | |
Interest | Rs m | 671 | 452 | 553 | 546 | 651 | |
Profit before tax | Rs m | 8,451 | 9,646 | 9,260 | 9,547 | 12,598 | |
Minority Interest | Rs m | -114 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 1,606 | 600 | 2,876 | 1,810 | 1,105 | |
Profit after tax | Rs m | 6,731 | 9,047 | 6,384 | 7,736 | 11,493 | |
Gross profit margin | % | 17.0 | 17.1 | 16.0 | 15.2 | 17.7 | |
Effective tax rate | % | 19.0 | 6.2 | 31.1 | 19.0 | 8.8 | |
Net profit margin | % | 13.5 | 15.5 | 9.9 | 10.5 | 13.8 |
ALKEM LABORATORIES BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 27,062 | 29,171 | 39,152 | 42,161 | 54,960 | |
Current liabilities | Rs m | 15,324 | 16,897 | 23,833 | 22,175 | 32,433 | |
Net working cap to sales | % | 23.5 | 21.0 | 23.8 | 27.2 | 27.0 | |
Current ratio | x | 1.8 | 1.7 | 1.6 | 1.9 | 1.7 | |
Inventory Days | Days | 67 | 75 | 82 | 74 | 80 | |
Debtors Days | Days | 41 | 45 | 61 | 62 | 72 | |
Net fixed assets | Rs m | 12,610 | 20,963 | 26,646 | 30,234 | 32,710 | |
Share capital | Rs m | 239 | 239 | 239 | 239 | 239 | |
"Free" reserves | Rs m | 34,490 | 44,437 | 48,399 | 54,154 | 61,368 | |
Net worth | Rs m | 35,027 | 44,676 | 48,638 | 54,393 | 61,607 | |
Long term debt | Rs m | 1,212 | 1,816 | 1,307 | 2,313 | 1,592 | |
Total assets | Rs m | 54,387 | 65,681 | 76,656 | 82,082 | 99,433 | |
Interest coverage | x | 13.6 | 22.4 | 17.7 | 18.5 | 20.4 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.9 | 0.9 | 0.8 | 0.9 | 0.8 | |
Return on assets | % | 13.6 | 14.5 | 9.1 | 10.1 | 12.2 | |
Return on equity | % | 19.2 | 20.2 | 13.1 | 14.2 | 18.7 | |
Return on capital | % | 24.9 | 21.7 | 19.6 | 17.8 | 21.0 | |
Exports to sales | % | 12.9 | 12.4 | 15.5 | 16.5 | 19.1 | |
Imports to sales | % | 3.1 | 3.3 | 3.3 | 2.9 | 3.0 | |
Exports (fob) | Rs m | 6,461 | 7,242 | 9,942 | 12,160 | 15,917 | |
Imports (cif) | Rs m | 1,540 | 1,903 | 2,103 | 2,105 | 2,483 | |
Fx inflow | Rs m | 6,563 | 8,410 | 11,259 | 12,238 | 16,061 | |
Fx outflow | Rs m | 3,012 | 1,903 | 2,103 | 2,105 | 2,483 | |
Net fx | Rs m | 3,552 | 6,507 | 9,156 | 10,133 | 13,578 |
ALKEM LABORATORIES CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 7,259 | 4,711 | 2,762 | 7,797 | 5,851 | |
From Investments | Rs m | 1,864 | -2,859 | -3,674 | -3,164 | -7,414 | |
From Financial Activity | Rs m | -9,273 | -1,379 | 846 | -3,789 | 792 | |
Net Cashflow | Rs m | -150 | 396 | 1 | 823 | -731 |
Share Holding
|
Company Information
|
CHM: Mr. Samprada Singh | COMP SEC: Mr. Manish Narang | YEAR OF INC: 1973 | BSE CODE: 539523 | FV (Rs): 2 | DIV YIELD (%): 0.9 |
More Pharmaceuticals Company Fact Sheets: TTK HEALTHCARE STRIDES PHARMA SCIENCE NATCO PHARMA WYETH SANOFI INDIA
Compare ALKEM LABORATORIES With: TTK HEALTHCARE STRIDES PHARMA SCIENCE NATCO PHARMA WYETH SANOFI INDIA
Compare ALKEM LABORATORIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed positive trading activity throughout the day yesterday and ended on a strong note.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More